Principles of treatment of malignant neoplasms in kidney transplant recipients

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Treatment of malignant neoplasms in kidney transplant recipients has distinctive features compared to the non-transplant population. When a tumor is detected in recipients, immunosuppressive therapy is reduced or modified to enhance the natural immune system, followed by treatment. However, some medications that are standard in the non-transplant population are not used or are used only to a limited extent due to the increased risk of kidney graft rejection. The risk of graft rejection, difficulties in therapy, and small patient samples mean that some issues related to cancer treatment in kidney transplant recipients remain controversial and under study.

About the authors

Ruslan N. Trushkin

Moscow Clinical Research Center, Hospital No. 52 of the Moscow Healthcare Department

Author for correspondence.
Email: uro52@mail.ru
ORCID iD: 0000-0002-3108-0539

Dr.Sci. (Med.), Head of the Urology Department

Russian Federation, Moscow

Aleksandr A. Sokolov

Central Clinical Hospital with Policlinic of the Administrative Directorate of the President of the Russian Federation

Email: salexdoc@gmail.com
ORCID iD: 0009-0007-0302-0428

Cand.Sci. (Med.), Urologist

Russian Federation, Moscow

Sergey A. Sokolov

Moscow Clinical Research Center, Hospital No. 52 of the Moscow Healthcare Department

Email: sergey.sokolow28@mail.ru
ORCID iD: 0009-0004-7016-2360

Urologist, Urology Department

Russian Federation, Moscow

Teymur K. Isaev

Moscow Clinical Research Center, Hospital No. 52 of the Moscow Healthcare Department

Email: dr.isaev@mail.ru
ORCID iD: 0000-0003-3462-8616

Dr.Sci. (Med.), Urologist, Urology Department

Russian Federation, Moscow

Anastasia M. Isaeva

Central Clinical Hospital with Policlinic of the Administrative Directorate of the President of the Russian Federation

Email: antropik88@mail.ru

Gynecologist

Russian Federation, Moscow

References

  1. Wu B., Wang K., Mo C.B. et al. De novo malignancies in renal transplant recipients: experience at a single center in China. Int. J. Clin. Exp. Med. 2015;8(2):2911–6. [PMID: 25932254, PMCID: PMC4402901].
  2. Wimmer C.D., Rentsch M., Crispin A. et al. The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int. 2007;71(12):1271–8. doi: 10.1038/sj.ki.5002154. [Epub 2007 Feb 28, PMID: 17332737].
  3. Benoni H., Eloranta S., Dahle D.O. et al. Relative and absolute cancer risks among Nordic kidney transplant recipients-a population-based study. Transpl. Int. 2020;33(12):1700–10. doi: 10.1111/tri.13734. [Epub 2020 Sep 25, PMID: 32896035, PMCID: PMC7756726].
  4. Manickavasagar R., Thuraisingham R. Post renal-transplant malignancy surveillance. Clin. Med. (Lond). 2020;20(2):142–5. doi: 10.7861/clinmed.2019-0423. [PMID: 32188647, PMCID: PMC7081823].
  5. Srisuwarn P., Sutharattanapong N., Disthabanchong S. et al. Incidence of De Novo Post-Transplant Malignancies in Thai Adult Kidney Transplant Recipients: A Single-Center, Population-Controlled, Retrospective Cohort Study at the Highest Volume Kidney Transplant Center in Thailand. Transpl. Int. 2024;37:11614. doi: 10.3389/ti.2024.11614. [PMID: 38468637, PMCID: PMC10926888].
  6. Friman T.K., Jäämaa-Holmberg S., Åberg F. et al. Cancer risk and mortality after solid organ transplantation: A population-based 30-year cohort study in Finland. Int. J. Cancer. 2022;150(11):1779–91. doi: 10.1002/ijc.33934. [Epub 2022 Feb 3, PMID: 35041762, PMCID: PMC9306582].
  7. Bigotte Vieira M., Arai H., Nicolau C., et al. Cancer Screening and Cancer Treatment in Kidney Transplant Recipients. Kidney360. 2024;5(10):1569–83. doi: 10.34067/KID.0000000000000545. [PMID: 39480669, PMCID: PMC11556922].
  8. Schreiber B., Abdelrahim M., Abudayyeh A. et al. Emerging Concepts in Managing Malignancy in Kidney Transplant Patients. Semin. Nephrol. 2022;42(1):63–75. doi: 10.1016/j.semnephrol.2022.01.003. [PMID: 35618396, PMCID: PMC9139423].
  9. Knoll G.A., Kokolo M.B., Mallick R. et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ. 2014;349:g6679. doi: 10.1136/bmj.g6679. Erratum in: BMJ. 2014;349:g7543. [PMID: 25422259, PMCID: PMC4241732].
  10. Re Sartò G.V., Alfieri C., Cosmai L. et al. Post-Kidney Transplant Cancer: A Real-World Retrospective Analysis From a Single Italian Center. Transpl. Int. 2024;37:13220. doi: 10.3389/ti.2024.13220. [PMID: 39228659, PMCID: PMC11368674].
  11. Walavalkar V., Adey D.B., Laszik Z.G. et al. Severe Renal Allograft Rejection Resulting from Lenalidomide Therapy for Multiple Myeloma: Case Report. Transplant. Proc. 2018;50(3):873–6. doi: 10.1016/j.transproceed.2018.01.014. [PMID: 29661456].
  12. Yamshon S., Gribbin C., Chen Z. et al. Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis. Cell. Ther. Transplant. 2024;30(1):73.e1–73.e12. doi: 10.1016/j.jtct.2023.05.018. [Epub 2023 Jun 4, PMID: 37279856].
  13. Alzahrani N., Al Jurdi A., Riella L.V. Immune checkpoint inhibitors in kidney transplantation. Curr. Opin. Organ. Transplant. 2023;28(1):46–54. doi: 10.1097/MOT.0000000000001036. [Epub 2022 Nov 17, PMID: 36579684, PMCID: PMC9811500].
  14. Kawashima S., Joachim K., Abdelrahim M. et al. Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates. Korean J. Transplant. 2022;36(2):82–98. doi: 10.4285/kjt.22.0013. [Epub 2022 Jun 3, PMID: 35919193, PMCID: PMC9296977].
  15. Portuguese A.J., Tykodi S.S., Blosser C.D. et al. Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review. J. Natl. Compr. Canc. Netw. 2022;20(4):406–16.e11. doi: 10.6004/jnccn.2022.7009. [PMID: 35390767].
  16. d'Izarny-Gargas T., Durrbach A., Zaidan M. Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: A systematic review. Am. J. Transplant. 2020;20(9):2457–65. doi: 10.1111/ajt.15811. [Epub 2020 Mar 21, PMID: 32027461].
  17. Murakami N., Mulvaney P., Danesh M. et al. Immune Checkpoint Inhibitors in Solid Organ Transplant Consortium. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int. 2021;100(1):196–205. doi: 10.1016/j.kint.2020.12.015. [Epub 2020 Dec 24, PMID: 33359528, PMCID: PMC8222056].
  18. Holstein S.A., Lunning M.A. CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress. Clin. Pharmacol. Ther. 2020;107(1):112–22. doi: 10.1002/cpt.1674. [Epub 2019 Nov 25, PMID: 31622496].
  19. Guy P., Marion O., Oberic L. et al. CAR T-Cell Therapy for Refractory Posttransplantation Lymphoproliferative Disorder in a Kidney Transplant Patient. Transplant. Direct. 2024;10(3):e1584. doi: 10.1097/TXD.0000000000001584. [PMID: 38414975, PMCID: PMC10898664].
  20. Hernani R., Sancho A., Amat P. et al. CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review. Curr. Res. Transl. Med. 2021;69(4):103304. doi: 10.1016/j.retram.2021.103304. [Epub 2021 Jul 22, PMID: 34303899].
  21. Krishnamoorthy S., Ghobadi A., Santos R.D. et al. CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder. Am. J. Transplant. 2021;21(2):809–14. doi: 10.1111/ajt.16367. [Epub 2020 Dec 5, PMID: 33089906].
  22. Mamlouk O., Nair R., Iyer S.P. et al. Safety of CAR T-cell therapy in kidney transplant recipients. Blood. 2021;137(18):2558–62. doi: 10.1182/blood.2020008759. [PMID: 33512386, PMCID: PMC8109014].
  23. Luttwak E., Hagin D., Perry C. et al. Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease-a single center case series. Bone Marrow Transplant. 2021;56(5):1031–7. doi: 10.1038/s41409-020-01145-1. [Epub 2020 Nov 23, PMID: 33230187].
  24. Kline K., Chen W., Kallen M.E. et al. Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD). Hum. Vaccin. Immunother. 2023;19(2):2216116. doi: 10.1080/21645515.2023.2216116. [Epub 2023 Jun 6, PMID: 37278257, PMCID: PMC10305491].
  25. McKenna M., Epperla N., Ghobadi A. et al. Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD. Br. J. Haematol. 2023;202(2):248–55. doi: 10.1111/bjh.18828. [Epub 2023 May 2, PMID: 37129856].
  26. Portuguese A.J., Gauthier J., Tykodi S.S. et al. CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review. Bone Marrow Transplant. 2023;58(4):353–9. doi: 10.1038/s41409-022-01907-z. [Epub 2022 Dec 27, PMID: 36575360].
  27. Kluijfhout W.P., Drake F.T., Pasternak J.D. et al. De novo thyroid cancer following solid organ transplantation-A 25-year experience at a high-volume institution with a review of the literature. J. Surg. Oncol. 2017;115(2):105–8. doi: 10.1002/jso.24495. [Epub 2017 Jan 5, PMID: 28054345].
  28. Zimak Z., Mokos I., Saić H. et al. Management of prostate cancer in kidney transplant recipients. Acta Clin. Croat. 2023;62(Suppl. 2):110–3. doi: 10.20471/acc.2023.62.s2.15. [PMID: 38966025, PMCID: PMC11221233].
  29. Spatafora P., Sessa F., Caroassai Grisanti S. et al. Prostate Cancer Characteristics in Renal Transplant Recipients: A 25-Year Experience From a Single Centre. Front. Surg. 2021;8:716861. doi: 10.3389/fsurg.2021.716861. [PMID: 34395512, PMCID: PMC8358676].
  30. Schmidt J., Yakac A., Peters R. et al. Radical Prostatectomy in Kidney Transplant Recipients-A Multicenter Experience. Eur. Urol. Open Sci. 2024;67:45-53. doi: 10.1016/j.euros.2024.07.111. [PMID: 39175845, PMCID: PMC11339048].
  31. Dat A., Wei G., Knight S. et al. The role of localised prostate cancer treatment in renal transplant patients: A systematic review. BJUI Compass. 2023;4(6):622–58. doi: 10.1002/bco2.276. [PMID: 37818029, PMCID: PMC10560625].
  32. Marra G., Soria F., Peretti F. et al. Prostate Cancer in Renal Transplant Recipients: Results from a Large Contemporary Cohort. Cancers (Basel). 2022;15(1):189. doi: 10.3390/cancers15010189. [PMID: 36612184, PMCID: PMC9818510].
  33. Du C., Zheng M., Wang Z. et al. Clinical characteristics and treatment outcomes of kidney transplant recipients with de novo urothelial carcinoma: thirty years of experience from a single center. BMC. Urol. 2023;23(1):71. doi: 10.1186/s12894-023-01232-7. [PMID: 37118774, PMCID: PMC10148563].
  34. Chang N.W., Huang Y.H., Sung W.W. et al. Adjuvant Chemotherapy in Patients with Locally Advanced Upper Tract Urothelial Carcinoma with or without Kidney Transplantation. J. Clin. Med. 2024;13(7):1831. doi: 10.3390/jcm13071831. [PMID: 38610596, PMCID: PMC11012329].
  35. Alkassis M., Abi Tayeh G., Khalil N. et al. The safety and efficacy of Bacillus Calmette-Guerin intravesical therapy in kidney transplant recipients with superficial bladder cancer. Clin. Transplant. 2021;35(7):e14377. doi: 10.1111/ctr.14377. [Epub 2021 Jun 13, PMID: 34050983].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).